{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:02:12Z","timestamp":1791014532890,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T00:00:00Z","timestamp":1315526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T00:00:00Z","timestamp":1315526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1038\/cgt.2011.60","type":"journal-article","created":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T18:26:32Z","timestamp":1315592792000},"page":"906-912","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment of mesothelioma with gene-modified PA1STK cells and ganciclovir: a phase I study"],"prefix":"10.1038","volume":"18","author":[{"given":"P","family":"Schwarzenberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Gaumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Marrogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J K","family":"Kolls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,9,9]]},"reference":[{"key":"BFcgt201160_CR1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411\u2013422.","journal-title":"N Engl J Med"},{"key":"BFcgt201160_CR2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711\u2013723.","journal-title":"N Engl J Med"},{"key":"BFcgt201160_CR3","first-page":"279","volume":"1","author":"FL Moolten","year":"1994","unstructured":"Moolten FL . Drug sensitivity suicide genes for selective cancer chemotherapy. Cancer Gene Ther 1994; 1: 279\u2013287.","journal-title":"Cancer Gene Ther"},{"key":"BFcgt201160_CR4","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1016\/S0006-291X(82)80109-5","volume":"108","author":"WT Ashton","year":"1982","unstructured":"Ashton WT, Karkas JD, Field AK, Tolman RL . Activation by thymidine kinase and potent antiherpetic activity of 2\u2032-nor-2\u2032-deoxyguanosine (2\u2032NDG). Biochem Biophys Res Commun 1982; 108: 1716\u20131721.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFcgt201160_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/jlb.56.2.203","volume":"56","author":"P Tiberghien","year":"1994","unstructured":"Tiberghien P . Use of suicide genes in gene therapy. J Leukoc Biol 1994; 56: 203\u2013209.","journal-title":"J Leukoc Biol"},{"key":"BFcgt201160_CR6","first-page":"5274","volume":"53","author":"SM Freeman","year":"1993","unstructured":"Freeman SM, Abboud CN, Whartenby KA, Packman CH, Koeplin DS, Moolten FL et al. The \u2018bystander effect\u2019: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274\u20135283.","journal-title":"Cancer Res"},{"key":"BFcgt201160_CR7","first-page":"829","volume":"24","author":"R Ramesh","year":"1996","unstructured":"Ramesh R, Marrogi AJ, Munshi A, Abboud CN, Freeman SM . In vivo analysis of the \u2018bystander effect\u2019: a cytokine cascade. Exp Hematol 1996; 24: 829\u2013838.","journal-title":"Exp Hematol"},{"key":"BFcgt201160_CR8","first-page":"31","volume":"23","author":"SM Freeman","year":"1996","unstructured":"Freeman SM, Whartenby KA, Freeman JL, Abboud CN, Marrogi AJ . In situ use of suicide genes for cancer therapy. Semin Oncol 1996; 23: 31\u201345.","journal-title":"Semin Oncol"},{"key":"BFcgt201160_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1165\/ajrcmb.19.2.3123","volume":"19","author":"P Schwarzenberger","year":"1998","unstructured":"Schwarzenberger P, Lei D, Freeman SM, Ye P, Weinacker A, Theodossiou C et al. Antitumor activity with the HSV-tk-gene-modified cell line PA-1-STK in malignant mesothelioma. Am J Respir Cell Mol Biol 1998; 19: 333\u2013337.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"BFcgt201160_CR10","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/(SICI)1097-0215(19990129)80:3<380::AID-IJC8>3.0.CO;2-G","volume":"80","author":"R Ramesh","year":"1999","unstructured":"Ramesh R, Munshi A, Marrogi AJ, Freeman SM . Enhancement of tumor killing using a combination of tumor immunization and HSV-tk suicide gene therapy. Int J Cancer 1999; 80: 380\u2013386.","journal-title":"Int J Cancer"},{"key":"BFcgt201160_CR11","first-page":"373","volume":"3","author":"R Ramesh","year":"1996","unstructured":"Ramesh R, Munshi A, Abboud CN, Marrogi AJ, Freeman SM . Expression of costimulatory molecules: B7 and ICAM up-regulation after treatment with a suicide gene. Cancer Gene Ther 1996; 3: 373\u2013384.","journal-title":"Cancer Gene Ther"},{"key":"BFcgt201160_CR12","first-page":"131","volume":"72","author":"KA Whartenby","year":"1995","unstructured":"Whartenby KA, Abboud CN, Marrogi AJ, Ramesh R, Freeman SM . The biology of cancer gene therapy. Lab Invest 1995; 72: 131\u2013145.","journal-title":"Lab Invest"},{"key":"BFcgt201160_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0140-6736(97)22001-5","volume":"349","author":"SM Freeman","year":"1997","unstructured":"Freeman SM, Ramesh R, Marrogi AJ . Immune system in suicide-gene therapy. Lancet 1997; 349: 2\u20133.","journal-title":"Lancet"},{"key":"BFcgt201160_CR14","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636\u20132644.","journal-title":"J Clin Oncol"},{"key":"BFcgt201160_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ejcts.2006.11.046","volume":"31","author":"M Lucchi","year":"2007","unstructured":"Lucchi M, Chella A, Melfi F, Dini P, Ambrogi M, Fino L et al. A phase II study of intrapleural immuno-chemotherapy, pleurectomy\/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma. Eur J Cardiothorac Surg 2007; 31: 529\u2013533; discussion 533-534.","journal-title":"Eur J Cardiothorac Surg"},{"key":"BFcgt201160_CR16","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO;2-3","volume":"83","author":"P Astoul","year":"1998","unstructured":"Astoul P, Picat-Joossen D, Viallat JR, Boutin C . Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study. Cancer 1998; 83: 2099\u20132104.","journal-title":"Cancer"},{"key":"BFcgt201160_CR17","first-page":"104","volume":"1","author":"P Schwarzenberger","year":"1999","unstructured":"Schwarzenberger P, Byrne P, Kolls JK . Immunotherapy-based treatment strategies for malignant mesothelioma. Curr Opin Mol Ther 1999; 1: 104\u2013111.","journal-title":"Curr Opin Mol Ther"},{"key":"BFcgt201160_CR18","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1089\/hum.1996.7.16-2047","volume":"7","author":"J Treat","year":"1996","unstructured":"Treat J, Kaiser LR, Sterman DH, Litzky L, Davis A, Wilson JM et al. Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: a phase 1 trial (BB-IND 6274). Hum Gene Ther 1996; 7: 2047\u20132057.","journal-title":"Hum Gene Ther"},{"key":"BFcgt201160_CR19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0889-8588(05)70008-3","volume":"12","author":"DH Sterman","year":"1998","unstructured":"Sterman DH, Kaiser LR, Albelda SM . Gene therapy for malignant pleural mesothelioma. Hematol Oncol Clin North Am 1998; 12: 553\u2013568.","journal-title":"Hematol Oncol Clin North Am"},{"key":"BFcgt201160_CR20","first-page":"2641","volume":"9","author":"P Schwarzenberger","year":"1998","unstructured":"Schwarzenberger P, Harrison L, Weinacker A, Marrogi A, Byrne P, Ramesh R et al. The treatment of malignant mesothelioma with a gene modified cancer cell line: a phase I study. Hum Gene Ther 1998; 9: 2641\u20132649.","journal-title":"Hum Gene Ther"},{"key":"BFcgt201160_CR21","first-page":"5276","volume":"46","author":"FL Moolten","year":"1986","unstructured":"Moolten FL . Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276\u20135281.","journal-title":"Cancer Res"},{"key":"BFcgt201160_CR22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/jnci\/82.4.297","volume":"82","author":"FL Moolten","year":"1990","unstructured":"Moolten FL, Wells JM . Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990; 82: 297\u2013300.","journal-title":"J Natl Cancer Inst"},{"key":"BFcgt201160_CR23","first-page":"209","volume":"10","author":"P Ljungman","year":"1995","unstructured":"Ljungman P . Cytomegalovirus pneumonia: presentation, diagnosis, and treatment. Semin Respir Infect 1995; 10: 209\u2013215.","journal-title":"Semin Respir Infect"},{"key":"BFcgt201160_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0003-4975(00)01557-5","volume":"70","author":"LH Harrison","year":"2000","unstructured":"Harrison LH, Schwarzenberger PO, Byrne PS, Marrogi AJ, Kolls JK, McCarthy KE . Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma. Ann Thorac Surg 2000; 70: 407\u2013411.","journal-title":"Ann Thorac Surg"},{"key":"BFcgt201160_CR25","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/mt.2009.309","volume":"18","author":"DH Sterman","year":"2010","unstructured":"Sterman DH, Recio A, Haas AR, Vachani A, Katz SI, Gillespie CT et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther 2010; 18: 852\u2013860.","journal-title":"Mol Ther"},{"key":"BFcgt201160_CR26","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1165\/rcmb.2010-0026RT","volume":"42","author":"A Vachani","year":"2010","unstructured":"Vachani A, Moon E, Wakeam E, Albelda SM . Gene therapy for mesothelioma and lung cancer. Am J Respir Cell Mol Biol 2010; 42: 385\u2013393.","journal-title":"Am J Respir Cell Mol Biol"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cgt201160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201160","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cgt201160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,22]],"date-time":"2022-03-22T12:35:17Z","timestamp":1647952517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cgt201160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,9]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["BFcgt201160"],"URL":"https:\/\/doi.org\/10.1038\/cgt.2011.60","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,9]]},"assertion":[{"value":"12 April 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}